Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.
The approval of the vaccine, called mFLUSIVA, which is manufactured by Moderna, follows a series of blows to mRNA research ...
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...
FLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved productCompany expects supply to be ...
The Food and Drug Administration on Wednesday approved the U.S.’s first flu shot that uses mRNA technology: mFlusiva, from ...
Moderna received FDA approval for its new mRNA-based flu shot for older adults after months of regulatory questioning.
StockStory.org on MSN
Moderna (MRNA): Buy, sell, or hold post Q2 earnings?
What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was ...
Researchers found the shot to be about 27% more effective than the standard flu shot ...
If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine.
The FDA has approved Moderna’s influenza vaccine, the first licensed flu shot made using messenger RNA technology.
The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the ...
WASHINGTON (AP) — The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results